Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989
- PMID: 21694737
- PMCID: PMC3198144
- DOI: 10.1038/ejhg.2011.113
Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989
Erratum in
- Eur J Hum Genet. 2013 Sep;21(9):1031
Abstract
Neurofibromatosis 1 (NF1) is a comparatively common autosomal dominant disorder. However, relatively few studies have assessed lifetime risk; and information about the effect of NF1 on mortality remains uncertain. NF1 patients were identified using The North West regional family Genetic Register, which covers the 4.1 million people living in North West England, including the regions of Greater Manchester, Cheshire and Cumbria. Data relating to tumours and malignancies were obtained from The North West Cancer Intelligence Service. Death data for the general North West population were obtained from the Office of National Statistics. We identified 1186 individuals with NF1, of whom 1023 lived within the strict regional boundaries (constituting a region of North West England bound by The Pennines to the east and Irish Sea to the west, but excluding the conurbation of Liverpool (Merseyside) and the Wirral peninsula) and 131 had died. MPNST and glioma were found to be the two most common causes of reduced life expectancy among NF1 patients. In Kaplan-Meier analyses the median survival for NF1 patients was shown to be 71.5 years, with women living ∼7.4 years longer than men. On average both men and women lived ∼8 years less than their counterparts in the general population. Reduction in life expectancy for NF1 patients was found to be much lower (8 years) than the previously estimated 15-year decrease. Limitations relating to the underreporting of NF1 on death certificates were once again highlighted and should be considered in future investigations.
Figures
Similar articles
-
Malignant peripheral nerve sheath tumours in neurofibromatosis 1.J Med Genet. 2002 May;39(5):311-4. doi: 10.1136/jmg.39.5.311. J Med Genet. 2002. PMID: 12011145 Free PMC article.
-
Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.Orphanet J Rare Dis. 2011 May 4;6:18. doi: 10.1186/1750-1172-6-18. Orphanet J Rare Dis. 2011. PMID: 21542925 Free PMC article.
-
Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.Am J Hum Genet. 2001 May;68(5):1110-8. doi: 10.1086/320121. Epub 2001 Mar 28. Am J Hum Genet. 2001. PMID: 11283797 Free PMC article.
-
[SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].Epidemiol Prev. 2023 Jan-Apr;47(1-2 Suppl 1):1-286. doi: 10.19191/EP23.1-2-S1.003. Epidemiol Prev. 2023. PMID: 36825373 Italian.
-
The epidemiology of cardiovascular disease in the UK 2014.Heart. 2015 Aug;101(15):1182-9. doi: 10.1136/heartjnl-2015-307516. Epub 2015 Jun 3. Heart. 2015. PMID: 26041770 Free PMC article. Review.
Cited by
-
Case report: Benign and malignant tumors in adult patients with neurofibromatosis type 1: a comprehensive case series from a large oncologic reference center.Front Oncol. 2024 Jan 8;13:1291286. doi: 10.3389/fonc.2023.1291286. eCollection 2023. Front Oncol. 2024. PMID: 38260834 Free PMC article.
-
Lymphoproliferative malignancies in patients with neurofibromatosis 1.Orphanet J Rare Dis. 2021 May 19;16(1):230. doi: 10.1186/s13023-021-01856-8. Orphanet J Rare Dis. 2021. PMID: 34011343 Free PMC article.
-
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.PLoS One. 2012;7(4):e35711. doi: 10.1371/journal.pone.0035711. Epub 2012 Apr 27. PLoS One. 2012. PMID: 22558206 Free PMC article.
-
Pediatric malignancies in neurofibromatosis type 1: A population-based cohort study.Int J Cancer. 2019 Dec 1;145(11):2926-2932. doi: 10.1002/ijc.32187. Epub 2019 Feb 18. Int J Cancer. 2019. PMID: 30724342 Free PMC article.
-
Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.Am J Cancer Res. 2020 Mar 1;10(3):856-869. eCollection 2020. Am J Cancer Res. 2020. PMID: 32266095 Free PMC article.
References
-
- Sorensen SA, Mulvihill JJ, Nielsen A. Long term follow up of von Recklinghausen neurofibromatosis: survival and malignant neoplasms. N Engl J Med. 1986;314:1010–1015. - PubMed
-
- Zöller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol. 1995;75:136–140. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous